BCYC News and Press, Bicycle Therapeutics plc

2026-06-01 02:59:04 ET Editor's note: Seeking Alpha is proud to welcome Haolin Yin as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium ac...

2026-05-27 11:25:25 ET Investment Overview Read the full article on Seeking Alpha For further details see: Corbus Pharmaceuticals: I'd Preach Caution After Selloff On Latest Data Drop

In the dose optimization stage of the randomized Phase 2 trial (Duravelo-2), zelenectide pevedotin at its optimal dose in combination with pembrolizumab demonstrated response rates comparable to published data for standard of care (SOC) in patients with previously untreated metastatic urothelial ...

2026-04-30 17:15:03 ET Maury Raycroft from Jefferies issued a price target of $12.00 for BCYC on 2026-04-30 19:50:39. The adjusted price target was set to $12.00. At the time of the announcement, BCYC was trading at $4.72. The overall price target consensus is at $10.75 ...

2026-04-30 07:27:28 ET More on Bicycle Therapeutics Bicycle Therapeutics changes priorities, announces layoffs Seeking Alpha’s Quant Rating on Bicycle Therapeutics Historical earnings data for Bicycle Therapeutics Financial information for Bicycle Ther...

Presentations at AACR Annual Meeting 2026 underscore significant opportunities for nuzefatide pevedotin in EphA2 expressing cancers, including pancreatic cancer Human imaging data provides further evidence of the potential of EphA2 as a novel cancer target and the positive properties of B...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced an oral presentation and multiple poster presentations across five abstracts at t...

Phase 1 combination data of 6.5mg/m 2 Q2W nuzefatide pevedotin plus nivolumab demonstrate an encouraging preliminary efficacy profile with a differentiated tolerability profile in previously treated metastatic urothelial cancer Nuzefatide pevedotin demonstrates potent preclinical anti...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced an oral presentation and multiple poster presentations of five abstracts at the A...

2026-03-17 20:54:19 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers' 13F stock portfolio on a quarterly basis. It is based on Baker Brothers' regulatory 13F Form filed on 02/17/2026. The 13F portfolio value increased from $...